Literature DB >> 1952955

[Adhesion molecules and cancer metastasis].

H Shiozaki1, T Mori.   

Abstract

In accordance with the recent development of molecular biology and genetic technology for the study of adhesion molecule of cell-cell and cell-extracellular matrix interaction, correlation of these interactions with cancer metastasis have been progressing rapidly. For several years, active peptides derived from extracellular matrix (RGD) in fibronectin, YIGSR in laminin) have been used to inhibit tumor cell adhesion receptors, and block malignant cell adhesion and metastatic properties. Recently we have investigated the correlation between expression of cell-cell adhesion molecule (Ecadherin: E-CD) and metastasis in human esophageal, gastric and breast cancers by immunohistochemical staining using anti-human E-CD antibody (HE-CD-1). E-CD expression of these tumors was reduced in more than half cases when compared to normal epithelium. Moreover, E-CD expression of metastatic tumor in the primary sites was reduced significantly more than that of non-metastatic tumor. These results indicate that a firmly formed cluster of tumor cells might detach from the tumor nests with unstable adhesiveness, transit in the circulation and form metastatic foci in the secondary sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952955

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Correlation of N-cadherin expression in high grade gliomas with tissue invasion.

Authors:  Kenichiro Asano; Christopher D Duntsch; Qihong Zhou; James D Weimar; Dwight Bordelon; Jon H Robertson; Tayebeh Pourmotabbed
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

2.  Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells.

Authors:  Sanita Bharti; Heike Handrow-Metzmacher; Silvia Zickenheiner; Andreas Zeitvogel; Rudolf Baumann; Anna Starzinski-Powitz
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.